linjc16/ctgov huggingface dataset:
Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

Study Overview
=================
Brief Summary
-----------------
To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.

Official Title
-----------------
Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

Conditions
-----------------
Prostatic Neoplasms

Intervention / Treatment
-----------------
* Procedure: Hypo-fractionated Radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:- Eligible patients will have clinical stage T1c through T2b, initial PSA level <10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores involved. Patients who have had any form of prior curative treatment (surgery, radiotherapy, cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3 months duration will be allowed. Adult men will be considered. No life expectancy restrictions will apply. Performance Status will not be considered. No requirements for organ or marrow function will be made Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria:- No prior prostate treatment will be allowed. The use of other concurrent Investigational Agents will not be allowed. No exclusion requirements due to co-morbid disease or incurrent illness. No requirements regarding history of allergic reactions. Pregnancy or nursing patients is not applicable (ie. patients are male).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Hypo-fractionated Radiotherapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PSA response that achieves a stable nadir over time. |  |  |
Deep Learning Model for Pure Solid Nodules Classification

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the predictive performance of a CT-based deep learning model for pure-solid nodules classification and compared with the tumor maximum standardized uptake value on PET in a multicenter prospective cohort.

Official Title
-----------------
Deep Learning Model Supplementary PET-CT as a More Effectively Diagnostic Method for Pure Solid Nodules Classification: a Multicenter Observational Study

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: CT-based deep learning model


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants scheduled for surgery for radiological finding of pulmonary pure-solid lesions from the preoperative thin-section CT scans; The maximum short-axis diameter of lymph nodes less than 3 cm on CT scan; Age ranging from 18-75 years; definied pathological examination report available; Obtained written informed consent. Exclusion Criteria: Multiple lung lesions; Poor quality of CT images; Participants with incomplete clinical information; Participants who have received neoadjuvant therapy before initial CT evaluation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: CT-based deep learning model|CT-based deep learning model for pure-solid nodules classifications|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC | Area under the curve of the receiver operating characteristic | 2022.01-2023.12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy | Ratio of the number of correctly classified samples to the total number of samples | 2022.01-2023.12 | 
| sensitivity | The probability of detecting a positive test in the population with the gold standard for disease (positive) | 2022.01-2023.12 | 
| Specificity | Odds of detecting a negative test in a population judged disease-free (negative) by the gold standard | 2022.01-2023.12 | 
| PPV | Positive predictive value | 2022.01-2023.12 | 
| NPV | Negative predictive value | 2022.01-2023.12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
deep learning model, pure-solid nodules, PET-CT
The Effects of Dexmedetomidine Dose on Motor Evoked Potentials

Study Overview
=================
Brief Summary
-----------------
This a parallel group, two-arm, randomized superiority trial that will compare the effect of two different doses of dexmedetomidine on motor evoked potentials during spine surgery

Detailed Description
-----------------
This a parallel group, two-arm, randomized superiority trial that will compare the effect of two different doses of dexmedetomidine on suitability of motor evoked potentials for intraoperative monitoring during spine surgery

Official Title
-----------------
The Effects of Dexmedetomidine Dose on Motor Evoked Potentials During Spine Surgery: A Randomized, Single-blind Trial

Conditions
-----------------
Spinal Fusion

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing multi-level posterior spine fusions requiring motor evoked potential monitoring Exclusion Criteria: Allergy to dexmedetomidine, propofol Conditions knows to make recording of motor evoked potentials difficult, including poorly controlled diabetes, severe peripheral neuropathy, severe myelopathy, or previous surgery during which motor evoked potentials were difficult to obtain Hepatic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: High dose dexmedetomidine<br>Patients will receive dexmedetomidine 0.5 mcg/kg/hr plus propofol 50 mcg/kg/min | Drug: Dexmedetomidine<br>* Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.<br>* Other names: Precedex;|
| Active Comparator: Low dose dexmedetomidine<br>Patients will receive dexmedetomidine 1.0 mcg/kg/hr plus propofol 25 mcg/kg/min | Drug: Dexmedetomidine<br>* Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.<br>* Other names: Precedex;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of Patients With Monitorable of Motor Evoked Potentials | Monitorable is defined as stable signals being present in 3 muscles in each lower extremity, with mean peak-to-peak amplitude of at least 50 uV, and with mean-normalized interquartile variability of 0.9 or less. | During a single surgery for the duration of the operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
motor evoked potentials
Lymphedema Screening

Study Overview
=================
Brief Summary
-----------------
Breast cancer-related lymphedema is one of the most common and feared consequences of breast cancer treatment. Currently, there is no established screening program for lymphedema. This cross-sectional study will investigate diagnostic modalities in screening for lymphedema in patients with and without known lymphedema after breast cancer.

Official Title
-----------------
Screening for Lymphedema

Conditions
-----------------
Lymphedema

Intervention / Treatment
-----------------
* Diagnostic Test: Circumference tape measurements
* Diagnostic Test: Indocyanine green lymphangiography
* Diagnostic Test: bioimpedance spectroscopy
* Diagnostic Test: Symptom score


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previous breast cancer treated with axillary lymph node dissection No recurrence Understand the study Can talk, read and understand Danish Exclusion Criteria: Pregnant or breast feeding Lymph node dissection from other basins Psychiatric disorder Not possible to perform indocyanine green lymphangiography
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Breast cancer patients with lymphedema<br> | Diagnostic Test: Circumference tape measurements<br>* centimeter and volume criterias<br>Diagnostic Test: Indocyanine green lymphangiography<br>* Presence of dermal backflow<br>Diagnostic Test: bioimpedance spectroscopy<br>* 7.5 and 10 L-DEX criterias<br>Diagnostic Test: Symptom score<br>* using lymph-icf, DASH and SF-36 questionnaires<br>|
| Other: Breast cancer patients without lymphedema<br> | Diagnostic Test: Circumference tape measurements<br>* centimeter and volume criterias<br>Diagnostic Test: Indocyanine green lymphangiography<br>* Presence of dermal backflow<br>Diagnostic Test: bioimpedance spectroscopy<br>* 7.5 and 10 L-DEX criterias<br>Diagnostic Test: Symptom score<br>* using lymph-icf, DASH and SF-36 questionnaires<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sensitivity, specificy, NPV and PPV | diagnosotic statistics of lymphedema measurements | through study completion, approximately 1 year |
Carbon Dioxide Versus Air Insufflation in Oesophago-gastro-duodenoscopy (OGD)

Study Overview
=================
Brief Summary
-----------------
Comparison on the effect on patient pain and discomfort by using CO2 instead of air for insufflation during gastroscopy.

Detailed Description
-----------------
To achieve a satisfactory examination of the GI tract it needs to be distended during endoscopic procedures. After the examinations many patients complain of abdominal pain and discomfort. This pain has been substantially reduced by substituting room air with CO2 in both colonoscopies and ERCPs. The use of CO2 during colonoscopy has become routine practice at many endoscopy centers. In our study we will test the hypothesis that abdominal pain after gastroscopies also can be reduced by substituting room air with CO2.

Official Title
-----------------
A Double-blinded, Randomized Trial Comparing Carbondioxide(CO2)and Air Insufflation in Oesophago-gastro-duodenoscopy (OGD)

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Procedure: CO2 insufflation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for OGD at the outpatient clinic of Telemark Hospital Exclusion Criteria: Age <18 Inability to give an informed concent Unsatisfactory norwegian language skills Patients not willing to participate COPD with dyspnoea NYHA 3-4

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Room air insufflation<br>Air used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is current standard procedure, i.e. no experimental intervention. | |
| Experimental: CO2 insufflation<br>CO2 used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is not standard procedure and therefore experimental intervention. | Procedure: CO2 insufflation<br>* From the CO2 rack through the endoscopy rack CO2 will be insufflated to visualize the mucosa during oesophagogastroduodenoscopy.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain after OGD |  | 0-48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain during OGD |  | 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
quality assessment, pain reduction, gastroscopy, carbondioxide insufflation, Patient satisfaction
Validation of Two New Questionnaires for Dupuytren's Disease

Study Overview
=================
Brief Summary
-----------------
A study to validate two newly developed questionnaires for Dupuytren's Disease. The objective is to develop a patient specific outcomes tool for Dupuytren's Disease. While there are standard and validated questionnaire instruments used to measure health related quality of life and function, they do not address patient specific issues. The investigators will also pilot a treatment/disease specific satisfaction questionnaire for Xiaflex use for Dupuytren's Disease.

Official Title
-----------------
A Prospective Study to Validate Two New Patient Reported Outcome Measures for Dupuytren's Disease in Patients Treated With XIAFLEX

Conditions
-----------------
Dupuytren's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject has a diagnosis of Dupuytren's Disease in at least one finger Patients will be 35 years of age or older Patients will be able to read, speak, and understand English Patients will be able to provide voluntary written consent to participate Exclusion Criteria: Female patients who are nursing or pregnant, or plan to become pregnant during the treatment phase. Patient has a chronic muscular, neurological or neuromuscular disorder that affects the hands. Patient has a known allergy to collagenase or any other excipient of XIAFLEX. Patient has received any collagenase treatments before the first dose of XIAFLEX. Any history of or current medical condition which in the investigator's opinion would make the subject unsuitable for enrollment in the study

Ages Eligible for Study
-----------------
Minimum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QuickDASH (Disability of the Arm, Shoulder, and Hand) |  | 30 day follow up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dupuytren's Contracture
The Effect of Whey Protein on Short-Term Food Intake and Post-Meal Blood Glucose Response in Young Men

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to describe relationships among whey protein when consumed before a meal on food intake and pre- and post-meal satiety, blood glucose in healthy young adults.

Detailed Description
-----------------
A randomized, cross-over design study was conducted. Whey protein preloads (10-40 g) were provided in 300 ml water. At 30 min following consumption, subjects were fed an ad libitum pizza meal. Satiety, and blood glucose were measured at baseline and selected intervals pre- (0, 15 and 30 min) and post-meal (50, 65, 80 and 95 min).

Official Title
-----------------
The Effect of Whey Protein on Short-term Food Intake and Post-meal Blood Glucose Response in Young Men

Conditions
-----------------
Diabetes Prevention, Obesity Prevention

Intervention / Treatment
-----------------
* Other: dietary intervention
* Other: water control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy normal weight ( 18-24.9 kg/m²) young aged 20-27 year old Exclusion Criteria: breakfast skippers smokers dieters individuals with diabetes (fasting BG ≥ 7.0 mmol/L) or other metabolic diseases

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 27 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 10 g whey protein<br> | Other: dietary intervention<br>* whey protein 10-40 g<br>|
| Experimental: 20 g whey protein<br> | Other: dietary intervention<br>* whey protein 10-40 g<br>|
| Experimental: 30 g whey protein<br> | Other: dietary intervention<br>* whey protein 10-40 g<br>|
| Experimental: 40 g whey protein<br> | Other: dietary intervention<br>* whey protein 10-40 g<br>|
| Experimental: water control<br>Iso-volumetric (300 ml) water control (Crystal Springs, Canada) | Other: water control<br>* Iso-volumetric (300 ml) water control (Crystal Springs, Canada)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood glucose subjective appetite Food intake at 30 min |  | 0-95 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| physical comfort palatability |  | 0-95 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
whey protein, subjective appetite, shor-term food intake, blood glucose
Evaluation of Postoperative Pain Following Bascom Cleft Lift Operation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate postoperative pain in Bascom Cleft Lift operation receiving multimodal analgesia in day-case surgery setting. Hypothesis: Multimodal analgesia provides adequate pain relief in patients undergoing Bascom Cleft Lift operation.

Official Title
-----------------
Evaluation of Post-operative Pain in Bascom Cleft Lift Operation Receiving Multimodal Analgesia and Spinal Saddle Block in Day Case Surgery Setting.

Conditions
-----------------
Postoperative Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 ASA physical status 1 and 2 Patient undergoing Bascom operation in prone position Exclusion Criteria: Pregnancy Current regular use of drug belonging to the class of opioids Allergy/ intolerance to drugs included in multimodal analgesia regime

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients undergoing Bascom operation<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numerical Rating Scale (NRS) pain score (0=no pain, 10= maximum imaginable pain) |  | 24 hours postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numerical Rating Scale (NRS) pain score (0=no pain, 10= maximum imaginable pain) |  | 2 hours, 48 hours and 30 days postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postoperative pain, Multimodal analgesia, Bascom Cleft Lift, Day-case.
The Relation Between Plasma Irisin Level and Endothelial Dysfunction in Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
Irisin is a signaling protein that is released into the blood from skeletal muscle after proteolysis of the membrane protein FNDC5 . FNDC5, encoded by the Fndc5 gene. Irisin activity on subcutaneous white adipose tissue, both in culture and in vivo, stimulated UCP1 expression and induction of brown adipocytes in white adipose tissue depots, a process known as white fat ''browning''. Irisin increases total energy expenditure in animal models, and irisin expression in mice fed a high fat diet resulted in a significant improvement in glucose tolerance and a reduction in fasting insulin levels. Collectively, these data suggest that decreased serum irisin levels may be associated with the development of insulin resistance and Type 2 diabetes. Indeed, some studies showed that irisin levels were decreased in newly diagnosed Type 2 diabetes. Endothelial dysfunction is an early physiological event in atherosclerosis. However, to date, no data are available on the relationship between circulating irisin and endothelial dysfunction in diabetes. Therefore, the investigators hypothesized that circulating irisin level is associated with endothelial dysfunction.

Official Title
-----------------
The Relation Between Plasma Irisin Level and Endothelial Dysfunction in Type 2 Diabetes

Conditions
-----------------
Irisin, Endothelial Dysfunction, Type 2 Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: newly diagnosed type 2 diabetic patients aged 40～70 years Exclusion Criteria: Patients with hypertension and those with micro- and macroangiopathy, including nephropathy [urinary albumin excretion rate (UAER) > 20 μg/min], retinopathy (at least one microaneurysm or hemorrhage or exudates in either eye), neuropathy (pain in extremities, paresthesias, and absent tendon reﬂexes and/or absent vibration sense), coronary artery disease (myocardial infarction, ischemia electrocardiogram changes, and angina), cerebrovascular disease (transient ischemic attack or stroke), and peripheral vascular disease (the abolition of one or more peripheral arterial pulse and/or intermittent claudication and/or a past history of revascularization of the lower limbs) were excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| type 2 diabetes<br>We select 200 newly diagnosed type 2 diabetic patients. Plasma irisin levels will be measured, and endothelial function will be determined. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The relation between plasma irisin and endothelium-dependent vasodilation |  | 6 months |